Experience with IVIg in the treatment of patients with myasthenia gravis

Neurology

Volumn 48, Issue 4 SUPPL. 5, 1997, Pages

  Dalakas, Marinos C ^a  

^a NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINERGIC RECEPTOR; IMMUNOGLOBULIN; IMMUNOGLOBULIN FC FRAGMENT;

ADULT; ANTIGEN RECOGNITION; CLINICAL ARTICLE; CLINICAL TRIAL; CONFERENCE PAPER; COST BENEFIT ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG MECHANISM; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRAVENOUS DRUG ADMINISTRATION; META ANALYSIS; MYASTHENIA GRAVIS; PRIORITY JOURNAL; RECEPTOR BINDING;

EID: 0030907223     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/wnl.48.suppl_5.64s     Document Type: Conference Paper

References (34)

1. Engel AG. Acquired autoimmune myasthenia gravis. In: Engel AG, Franzini-Armstrong C, eds. Myology. New York: McGraw-Hill, 1994:1769-1792.
2. Drachman DB. Myasthenia gravis. N Engl J Med 1994;330: 1797-1810.
3. Penn AS, Richman DP, Ruff RL, Lennon VA. Myasthenia gravis and related disorders. Ann NY Acad Sci 1993;681.
4. Dalakas MC. Neuroimmunotherapy: a practical approach to the treatment of immune-mediated neurological diseases. Semin Neurol 1994;14:97-105.
5. Arsura EL, Bick A, Brunner NG, Namba T, Grob D. High-dose intravenous immunoglobulin in the management of myasthenia gravis. Arch InterMed 1986;146:1365-1368.
6. Arsura EL, Bick A, Brunner NG, Grob D. Effects of repeated doses of intravenous immunoglobulin in myasthenia gravis. Am J Med Sci 1988;295:438-443.
7. Gajdos Ph, Outin HD, Morel E, Raphael JC, Goulon M. High dose intravenous gamma globulin for myasthenia gravis: an alternative to plasma exchange? Ann NY Acad Sci 1987;505: 843-844.
8. Gajdos Ph, Outin H, Elkharrat D, et al. High-dose intravenous gammaglobulin for myasthenia gravis. Lancet 1984;1:406-407.
9. Cosi V, Lombardi M, Piccolo G, Erbetta A. Treatment of myasthenia gravis with high-dose intravenous immunoglobulin. Acta Neurol Scand 1991;84:81-84.
10. Ippoliti G, Cosi V, Piccolo G, Lombardi M, Mantegaz R. High-dose intravenous gammaglobulin for myasthenia gravis. Lancet 1984;2:809.
11. Edan G, Landgraf. Experience with intravenous immunoglobulin in myasthenia gravis: a review. J Neurol Neurosurg Psychiatry 1994;57(suppl):55-56.
12. Besinger UA, Fateh-Moghadam A, Knorr-Held S, Wick M, Kissel H, Albiez M. Immunomodulation in myasthenia gravis by high dose intravenous 7-S immunoglobulin. Ann NY Acad Sci 1987;505:828-831.
13. Uchiyama M, Ichikawa Y, Takaya M, Moriuchi J, Shimizu H, Arimori S. High dose gamma globulin therapy of generalized myasthenia gravis. Ann NY Acad Sci 1987;505:868-870.
14. Cook L, Howard JF, Folds JD. Immediate effects of intravenous IgG administration on peripheral blood B and T cells and polymorphonuclear cells in patients with myasthenia gravis. J Clin Immunol 1988;8:23-31.
15. Sticker RB, Kwiatkowska BJ, Habis JA, Kiprov DD. Myasthenic crisis. Response to plasmapheresis following failure of intravenous γ-globulin. Arch Neurol 1993;50:837-840.
16. Gajdos Ph, Chastang Cl, Clair B, et al. First interim analysis of a randomized clinical trial comparing plasma exchange and intravenous immunoglobulin on myasthenia gravis. Neuromusc Dis 1996;4:S51.
17. Liblau R, Gajdos Ph, Bustardet FA, El Habib R, Bach JF, Morel E. Intravenous gamma globulin in myasthenia gravis: interaction with anti-acetylcholine receptor autoantibodies. J Clin Immunol 1991;11:128-131.
18. Dalakas MC. Intravenous immune globulin therapy for immune-mediated neurological diseases. Ann Inter Med (in press).
19. Avrameas S. Natural autoantibodies: from "horror autotoxicus" to "gnothi seauton." Immunol Today 1991;12:154-159.
20. Dwyer, JM. Manipulating the immune system with immune globulin. N Engl J Med 1992;326:107-116.
21. Tankersley DL, Preston MS, Finlayson JS. Immunoglobulin G dimer: an idiotype-anti-idiotype complex. Mol Immunol 1988; 25:41-48.
22. Jerne NK. The immune system: a web of V-domains. New York: Academic Press, 1976.
23. Uher F, Dickler HB. Cooperativity between B lymphocyte membrane molecules: independent ligand occupancy and crosslinking of antigen receptors and Fc gamma receptors downregulates B lymphocyte function. J Immunol 1986;137: 3124-3129.
24. Jungi TW, Nydegger VE. Proposed mechanisms of action of intravenous IgG in autoimmune diseases. Transfus Sci 1992; 13:267-290.
25. Vassilev T, Gelin C, Kaveri SV, Zilber MT, Boumsell L, Kazatchkine MD. Antibodies to the CD5 molecule in normal human immunoglobulins for therapeutic use (intravenous immunoglobulins, IVIg). Clin Exp Immunol 1993;92:369-372.
26. Svenson M, Hansen MB, Bendtzen K. Binding of cytokines to pharmaceutically prepared human immunoglobulin. J Clin Invest 1993;92:2533-2539.
27. Basta M, Dalakas MC. High-dose intravenous immunoglobulin exerts its beneficial effect in patients with dermatomyositis by blocking endomysial deposition of activated complement fragments. J Clin Invest 1994;94:1729-1735.
28. Dalakas MC. Basic aspects of neuroimmunology as they relate to immunotherapeutic targets: present and future prospects. Ann Neurol 1995;37(suppl)2-13.
29. 8 and HLA molecules in commercial immunoglobulin preparations. Lancet 1993;341:789-790.
30. Koffman B, Dalakas MC. Effect of high dose intravenous immunoglobulin on hematological and serum chemistry profiles in the treatment of patients with neuromuscular diseases. Neurology 1995;45(suppl):235.
31. Engelhard D, Waner JL, Kapoor N, Good RA. Effect of intravenous immune globulin on natural killer cells activity: possible association with autoimmune neutropenia and idiopathic thrombocytopenia. J Pediatr 1986;108:77-81.
32. Takei S, Arora YK, Walker SM. Intravenous immunoglobulin contains specific antibodies inhibitory to activation of T cells by staphylococcal toxin superantigens. J Clin Invest 1993;91: 602-607.
33. Kurlander RJ. Reversible and irreversible loss of Fc receptor function of human monocytes as a consequence of interaction with immunoglobulin G. J Clin Invest 1980;66:773-781.
34. Kaveri S, Vassilev T, Hurez V, et al. Antibodies to a conserved region of HLA class I molecule capable of modulating CD8 T cells mediated function, are present in pooled normal immunoglobulin for therapeutic use. J Clin Invest 1996;97:868-869.